Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Intellia Therapeutics (NTLA) Receivables - Net (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Receivables - Net for 11 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 11.17% to $9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.5 million, a 11.17% increase, with the full-year FY2025 number at $9.5 million, up 11.17% from a year prior.
  • Receivables - Net was $9.5 million for Q4 2025 at Intellia Therapeutics, down from $11.0 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $36.5 million in Q4 2023 to a low of $953000.0 in Q1 2021.
  • A 5-year average of $9.1 million and a median of $5.8 million in 2023 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: tumbled 92.87% in 2021, then skyrocketed 867.52% in 2023.
  • Intellia Therapeutics' Receivables - Net stood at $2.0 million in 2021, then skyrocketed by 85.52% to $3.8 million in 2022, then surged by 867.52% to $36.5 million in 2023, then crashed by 76.64% to $8.5 million in 2024, then grew by 11.17% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Receivables - Net are $9.5 million (Q4 2025), $11.0 million (Q3 2025), and $11.4 million (Q2 2025).